189 related articles for article (PubMed ID: 18611121)
1. Pravastatin: an evidence-based statin?
del Sol AI; Nanayakkara PW
Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):821-5. PubMed ID: 18611121
[TBL] [Abstract][Full Text] [Related]
2. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol lowering with statins: how WOSCOPS confounded the skeptics.
Shepherd J
Atheroscler Suppl; 2007 Aug; 8(2):9-12. PubMed ID: 17586101
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study.
Ford I; Murray H; McCowan C; Packard CJ
Circulation; 2016 Mar; 133(11):1073-80. PubMed ID: 26864092
[TBL] [Abstract][Full Text] [Related]
5. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care.
Eriksson M; Hådell K; Holme I; Walldius G; Kjellström T
J Intern Med; 1998 May; 243(5):373-80. PubMed ID: 9651560
[TBL] [Abstract][Full Text] [Related]
6. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
7. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.
Carlsson CM; Papcke-Benson K; Carnes M; McBride PE; Stein JH
Drugs Aging; 2002; 19(10):793-805. PubMed ID: 12390056
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
11. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
[TBL] [Abstract][Full Text] [Related]
13. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
Glorioso N; Troffa C; Filigheddu F; Dettori F; Soro A; Parpaglia PP; Collatina S; Pahor M
Hypertension; 1999 Dec; 34(6):1281-6. PubMed ID: 10601131
[TBL] [Abstract][Full Text] [Related]
14. Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese.
Teramoto T; Nakaya N; Yokoyama S; Ohashi Y; Mizuno K; Nakamura H;
J Atheroscler Thromb; 2010 Aug; 17(8):879-87. PubMed ID: 20543522
[TBL] [Abstract][Full Text] [Related]
15. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
[TBL] [Abstract][Full Text] [Related]
18. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly.
Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
Atherosclerosis; 2012 Feb; 220(2):413-7. PubMed ID: 22189199
[TBL] [Abstract][Full Text] [Related]
19. [New guidelines on treatment of blood cholesterol: too much of a good thing?].
Lippi G; Mattiuzzi C
Recenti Prog Med; 2014 Sep; 105(9):317-21. PubMed ID: 25229759
[TBL] [Abstract][Full Text] [Related]
20. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]